Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/zepbound/arizona/casa-grande
Dual GIP / GLP-1 receptor agonistFDA-approved November 2023Rx · Subcutaneous injection · Once weekly

Zepbound® providers &
prescriptions in Casa Grande, AZ

Verified Zepbound providers in Casa Grande, AZ. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Zepbound weight loss →trial-anchored estimate
city providers
23
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Arizona
23 of 23 shown

Find a Zepbound provider in Arizona.

Every entry is checked against the NPI registry and the Arizona medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Arizona city · /zepbound/arizona/{city}
Chandler
37 →
Gilbert
33.31°N
29 →
Mesa
34 →
Tempe
33.39°N
25 →
Goodyear
33.25°N
23 →
Phoenix
33.45°N
44 →
§ 03Getting Zepbound in Casa Grande
23 providers · Casa Grande, AZ

How to get Zepbound in Casa Grande.

23 GLP-1 prescribers and 7 local resource types are on record for Casa Grande, plus 3 nearby towns in the directory.

Prescribers in Casa Grande
23 prescribers
23 GLP-1 prescribers in Casa Grande, most listed as Family Medicine (13), Internal Medicine (7) and Phlebology (1). Any Arizona-licensed physician, nurse practitioner, or PA can prescribe Zepbound, over video or in person. The nearest towns on record are Chandler (37 providers), Gilbert (29 providers) and Mesa (34 providers).
Around the prescription in Casa Grande
7 listed nearby
5 dietitians, 2 nutritionists, 6 gyms, 5 fitness clubs, 4 trainers, 5 physiotherapists and 1 places to move are on record near Casa Grande.
Medicaid (weight loss)
Diabetes only
As of April 2026, Arizona Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Arizona’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.

Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
November 2023
Approved use
Chronic weight management (adults with obesity, or overweight with a weight-related condition)
Off-label use
Type 2 diabetes (Mounjaro is the FDA-approved tirzepatide for diabetes)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Casa Grande

Casa Grande, Arizona has a population of 53,658 people. The adult obesity rate in Casa Grande is an age-adjusted estimate of 40.2%, 6.9 percentage points above the Arizona state rate of 33.3%. Diagnosed diabetes reaches 11.8% of adults in Casa Grande. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 27.5% of adults in Casa Grande.

of Casa Grande adults have obesity
40.2%
diagnosed diabetes
11.8%
no regular physical activity
27.5%

Age-adjusted estimates for Casa Grande, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossdo oral GLP-1 pills work
§ 05Support around Zepbound in Casa Grande
5 fitness clubs

The prescription is one part. Here is the rest, in Casa Grande.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Casa Grande, AZ, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Planet Fitness
FITNESS
4.4 on Google · 760 reviews
Tri Valley Plaza, 1325 E Florence Blvd
Website
Casa Grande Community Recreation Center
REC CENTER
4.5 on Google · 167 reviews
1905 N Peart Rd
Website
Yerberia Casa Grande LLC
FITNESS
4.8 on Google · 30 reviews
201 W 2nd St
Ramos Boxing Academy
BOXING
5.0 on Google · 19 reviews
423 N Florence St
Website
Love Always Yoga & Fitness
STUDIO
4.9 on Google · 50 reviews
1269 N Promenade Pkwy #134
Website

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Germaine Davenport, CDM CFPP SNS CPFM
NUTRITIONIST
Nutritionist
1899 S Calle Del Marco
Call 520-280-4886NPI 1922598606
Krista Simonetti, MS, CNS
NUTRITIONIST
Nutritionist · Education
540 N Camino Mercado
Call 520-840-4026NPI 1043524689
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (10 mg)
−19.5%
SURMOUNT-1, 72 wk[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Zepbound weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Zepbound cash price (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Commercial insurance (weight)
Often denied
On-label for obesity but frequently requires prior authorization
Medicare Part D
Not covered
Weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance with coverage only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Zepbound providers in Arizona

NPI-verified Zepbound (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Weight loss doctors in Arizona
Board-certified prescribers verified against the NPI registry.
Weight loss clinics in Arizona
Clinics running GLP-1 programs, telehealth & in-person.
Zepbound in other states

Find NPI-verified Zepbound (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Zepbound in Alabama→Zepbound in Alaska→Zepbound in Arizona→Zepbound in Arkansas→Zepbound in California→Zepbound in Colorado→Zepbound in Connecticut→Zepbound in Delaware→Zepbound in Florida→Zepbound in Georgia→Zepbound in Hawaii→Zepbound in Idaho→Zepbound in Illinois→Zepbound in Indiana→Zepbound in Iowa→Zepbound in Kansas→Zepbound in Kentucky→Zepbound in Louisiana→Zepbound in Maine→Zepbound in Maryland→Zepbound in Massachusetts→Zepbound in Michigan→Zepbound in Minnesota→Zepbound in Mississippi→Zepbound in Missouri→Zepbound in Montana→Zepbound in Nebraska→Zepbound in Nevada→Zepbound in New Hampshire→Zepbound in New Jersey→Zepbound in New Mexico→Zepbound in New York→Zepbound in North Carolina→Zepbound in North Dakota→Zepbound in Ohio→Zepbound in Oklahoma→Zepbound in Oregon→Zepbound in Pennsylvania→Zepbound in Rhode Island→Zepbound in South Carolina→Zepbound in South Dakota→Zepbound in Tennessee→Zepbound in Texas→Zepbound in Utah→Zepbound in Vermont→Zepbound in Virginia→Zepbound in Washington→Zepbound in West Virginia→Zepbound in Wisconsin→Zepbound in Wyoming→
Related GLP-1 research
plateaus on Wegovy and Ozempic
The plateau playbook: dose, habits, and what the trials say.
the tirzepatide dosing schedule
Starting dose, step-ups, and the 2.5-to-15 mg ladder.
§ 09Frequently asked: Zepbound in Arizona

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]